3M PHARMACEUTICALS WILL FILE AIROMIR CFC-FREE METERED-DOSE INHALER
Executive Summary
3M PHARMACEUTICALS WILL FILE AIROMIR CFC-FREE METERED-DOSE INHALER NDA by the end of 1994. The company plans to file marketing applications globally by the close of the year and will first file for approval of Airomir containing 3M-produced albuterol. 3M will follow up with submissions for the inhaler containing the firm's beclomethasone. In the U.S., 3M will file NDAs that cover both the metered-dose inhaler and the asthma drugs.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth